Baer Investment Advisory LLC Purchases New Holdings in Amgen Inc. $AMGN

Baer Investment Advisory LLC acquired a new position in Amgen Inc. (NASDAQ:AMGN) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 2,657 shares of the medical research company’s stock, valued at approximately $935,000.

Other hedge funds have also made changes to their positions in the company. Robeco Institutional Asset Management B.V. lifted its stake in Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock worth $157,584,000 after purchasing an additional 43,884 shares in the last quarter. Curtis Advisory Group LLC acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $1,669,000. Adell Harriman & Carpenter Inc. lifted its position in Amgen by 7.9% during the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after buying an additional 1,609 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in Amgen during the fourth quarter worth $22,441,000. Finally, Robinhood Asset Management LLC acquired a new position in Amgen during the fourth quarter worth $17,526,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $374.15 on Friday. The company has a market capitalization of $201.93 billion, a price-to-earnings ratio of 26.04, a PEG ratio of 3.68 and a beta of 0.41. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $391.29. The business has a 50-day moving average price of $342.43 and a 200 day moving average price of $347.93. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. Amgen’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts expect that Amgen Inc. will post 22.39 EPS for the current year.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on AMGN. The Goldman Sachs Group set a $389.00 target price on Amgen in a research note on Friday, June 5th. Royal Bank Of Canada reissued a “positive” rating on shares of Amgen in a research report on Thursday, June 18th. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a report on Thursday, June 18th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $350.00 target price on shares of Amgen in a research note on Wednesday, April 8th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Amgen in a report on Friday, June 12th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $355.50.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.